AURA BIOPHARM 

First-in-class treatment for anti-phospholipid syndrome

OWNER

Ferdinando Nicoletti (See Profile)


Sector

Immunology

Stage

Prototyping, preclinical

Country

Norway

ONLY SPECIFIC TREATMENT AVAILABLE FOR APS

TARGETS PATHOGENIC MECHANISM OF APS

FIRST-IN-CLASS AND ORPHAN DRUG

NO OTHER SPECIFIC DRUG FOR APS UNDER DEVELOPMENT

ONLY OPTION FOR PATIENTS RESISTANT TO ANTICOAGULANT THERAPY

This information is confidential, do not share or copy.

You can visit their website or

Download the Pitch Deck

Under evaluation at least till: 2nd May 2018.

If you want to have more information or you want to review the project, you have to login or register

KEEP REVIEWING

©2023 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR
Aviso de cookies

Log in with your credentials

or    

Forgot your details?

Create Account

Skip to toolbar